A CGM makes normal biology visible and then frames it as a threat. What the sensor measures, what it cannot tell you, and who else receives the reading.
A continuous glucose monitor (CGM) is a medical device designed for people with Type 1 diabetes who cannot produce insulin at all and whose lives depend on knowing their blood glucose in real time. It is now being sold to healthy people without diabetes as a biohacking tool, and the marketing has repackaged a medical necessity as a wellness optimization device. These are not the same thing, and the distinction matters.
The body already has a CGM. It is called the pancreas. In someone without Type 1 diabetes, it responds to blood glucose changes faster and more precisely than any wearable device ever built. The sensor in a CGM measures interstitial fluid, not blood. It lags true blood glucose by 5–15 minutes and has a documented ±20% error margin. The pancreas has no lag and no error margin.
A CGM has three parts: a small sensor filament that is inserted under the skin (typically on the upper arm or abdomen), a transmitter that attaches over it, and a receiver (usually a phone app). The sensor filament, approximately 5–7mm long and coated with glucose oxidase enzyme, sits in the interstitial fluid between cells, not in a blood vessel. When glucose diffuses from capillaries into the interstitial space, the enzyme reacts with it and produces a small electrical current. That current is proportional to glucose concentration and is transmitted wirelessly to the app every few minutes.
The reading is an estimation of blood glucose, not a direct blood glucose measurement. Interstitial glucose lags blood glucose by 5–15 minutes during periods of rapid change (exercise, meals, stress). The sensor also degrades over its 10–14 day lifespan and can be affected by pressure (lying on it), temperature, and skin hydration. Despite marketing claims of "real-time" glucose insight, the data has inherent imprecision that manufacturers disclose in their clinical documentation, but not in their wellness marketing.
The sensor is placed with an auto-inserter that drives a needle through the skin. The needle retracts and the filament remains subcutaneously. This is a minor wound. It bypasses the skin barrier, the body's first line of immune defense, and creates a low-grade foreign body response at the insertion site. For a person managing Type 1 diabetes, this tradeoff is obvious. For a person without diabetes wearing one to see what happens to their glucose after a sweet potato, the risk-benefit calculus is different.
The transmitter communicates via Bluetooth and sometimes NFC, meaning the wearer is carrying a body-worn wireless transmitter continuously against their skin. For anyone already working to reduce non-native EMF exposure, a CGM is a constant, skin-contact EMF source. This concern is compounded when CGMs are marketed to parents for children, or when they are worn around the clock for weeks at a time as part of a "biohacking protocol."
Financial cost
Biological and psychological cost
Every CGM is a data collection device. The glucose data, timing patterns, activity correlations, and behavioral signatures generated by continuous biometric monitoring are transmitted to the manufacturer's cloud infrastructure. Most CGM wellness apps explicitly state in their terms of service that they may share de-identified (and sometimes identified) health data with third parties for research, product development, and commercial purposes.
What is actually being collected
The WEF 2020 white paper on the Internet of Bodies describes continuous biometric monitoring as "the next frontier of human data." CGMs, marketed as personal health empowerment tools, are simultaneously the most intimate form of continuous biosurveillance available to the consumer market. The data does not stay with the wearer.
If your concern is metabolic health, the variables that determine glucose regulation are knowable without a subcutaneous sensor:
A single night of poor sleep causes measurable insulin resistance the next day. No CGM needed to know this. You feel it. Fixing sleep does more for glucose regulation than any monitoring tool.
Voltage-gated calcium channel activation from wireless EMF disrupts mitochondrial function and insulin signaling. The CGM transmitter on your arm is adding to this load while you try to monitor the outcome.
Cortisol raises blood glucose directly. It is evolutionarily designed to mobilize fuel for a threat. A stressful morning meeting will spike your glucose as reliably as food. The CGM shows the number; it cannot show the cause. Seeing the spike without the context produces anxiety, which raises cortisol further.
A 10-minute walk after a meal reduces postprandial glucose spike by 30–50% in study populations. Free. No Bluetooth required. No skin penetration.
The driver of metabolic dysregulation is not sweet potatoes, fruit, or white rice. It is industrial processed seed oils, refined sugar, artificial sweeteners, and the absence of real food. A CGM monitoring the glucose response to a sweet potato versus a bag of chips shows different numbers, but any clinician, and most people, already know which is the problem. You do not need $3,000/year in sensors to make that distinction.
Clinical position
For a person with Type 1 diabetes (or Type 2 diabetes under insulin management) a CGM is a legitimate and valuable tool. For everyone else: the body already monitors glucose continuously, responds in real time, and communicates through symptoms you can learn to read. A subcutaneous sensor, a Bluetooth transmitter against your skin, and a corporate cloud receiving your biometric fingerprint is not health optimization. It is the monetization of manufactured fear about normal biology, and your data is the product.
The CGM is not a standalone wellness product. It is the most commercially successful entry point of a larger industry that positions itself as "life extension," "longevity medicine," and "human optimization", and that pipeline leads directly into the Internet of Bodies architecture described by the World Economic Forum.
The life extension industry: what it actually is
Glucose rises after eating. Heart rate varies. Sleep is inconsistent. Body weight fluctuates. The biohacking industry takes these normal physiological events, makes them visible on a screen, and teaches you to interpret them as threats. The device doesn't make you healthier. It makes you anxious and dependent on data.
The CGM sensor, the Oura ring, the continuous HRV tracker, the sleep monitor, the cortisol patch: each is a body-worn wireless device generating a continuous data stream: uploaded to a corporate server, sold to third parties, and used to train population-scale predictive health models. The consumer pays for the privilege of being the data source.
The investor and venture capital infrastructure behind CGM wellness companies substantially overlaps with the pharmaceutical "longevity" market. Andreessen Horowitz (a16z), which has backed Levels Health (a leading CGM wellness platform), has also invested in pharmaceutical longevity and metabolic drug companies. The same capital ecosystem that profits from monitoring your glucose also profits from selling interventions: metformin for non-diabetics, GLP-1 agonists (Ozempic/Wegovy) for weight loss, rapamycin, senolytics. The monitoring creates the anxiety. The anxiety creates the market. The data justifies the prescription. This is documented in SEC filings, VC portfolio disclosures, and company press releases, not speculation. The body becomes a managed system requiring continuous corporate inputs; what the conventional medicine model always was, rebranded as empowerment.
The WEF 2020 white paper Internet of Bodies explicitly identifies consumer wearables, including continuous health monitors, as tier-one IoB devices and describes this population-scale biometric infrastructure as "the next frontier of human data." The biohacking industry does not resist this architecture. It sells access to it, voluntarily, to the most health-conscious demographic, at premium prices, under the branding of personal sovereignty. People who believe they are taking control of their biology are financing and normalizing the infrastructure. The paper trail is public. Read the WEF white paper. Read the Levels Health terms of service. Read the CGM manufacturers' data-sharing policies. The intentions are not hidden. They are disclosed in the fine print no one reads.
The distinction that matters
Technology that helps a person with a genuine medical condition manage a life-threatening deficit. That is a tool. Technology that penetrates healthy skin, installs a wireless transmitter, uploads your metabolic fingerprint to a corporate database, and tells you your body is broken when it is functioning normally. That is not wellness. It is a business model dressed as health care, and the biohacking industry is its sales force.